UBS Group’s Medicines Co MDCO Stock Holding History

UBS Group’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-105,000	Closed	-$8.92M	–	8867
2019 Q4	$8.92M	Sell	105,000 -108,000	-51%	-$7.2M	﹤0.01%	2058
2019 Q3	$10.7M	Buy	213,000 +149,400	+235%	+$5.96M	﹤0.01%	1714
2019 Q2	$2.32M	Buy	+63,600	New	+$2.08M	﹤0.01%	3015
2016 Q4	–	Sell	-222,700	Closed	-$8.4M	–	8203
2016 Q3	$8.4M	Buy	+222,700	New	+$8.39M	0.01%	1565
2015 Q1	–	Sell	-400	Closed	-$11K	–	9670
2014 Q4	$11K	Buy	+400	New	+$9.91K	﹤0.01%	8346

Other funds holding MDCO

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

UBS Group's MDCO Position: Q1 2020 in Review

UBS Group sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 1,277,342 shares — an estimated $108M sold.

UBS Group first reported a position in MDCO in Q4 2014 and held it in 21 quarters. The position peaked at $108M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

UBS Group reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
UBS Group sold 1,277,342 Medicines Co shares in Q1 2020, an estimated $108M.
UBS Group first reported a position in Medicines Co in Q4 2014 and held it in 21 quarters.
UBS Group's Medicines Co position peaked at $108M in Q4 2019.
1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.